{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:14:19Z","timestamp":1783314859399,"version":"3.54.6"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Classic Hodgkin lymphoma (cHL) is highly curable for most patients with cytotoxic chemotherapy, while targeted agents such as brentuximab vedotin (BV) have been incorporated into frontline regimens. This single-center retrospective study aimed to compare the efficacy and safety of a local ABVD-like regimen and a BV-containing A-AVD-like regimen in Chinese patients with cHL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 243 cHL patients were enrolled, including 192 in ABVD and 51 in A-AVD. Baseline demographics, treatment outcomes, survival, and adverse events were analyzed; the median follow-up was 21.47 months. Subgroup analysis was performed including Ann Arbor stage and dose of Brentuximab Vedotin (BV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, the A-AVD group had a significantly higher proportion of elderly patients (\u226560 years) compared to the ABVD group (25.5% vs. 9.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.002). First-evaluation complete response (CR: 69.3% vs. 72.5%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.549) and overall response rate (ORR: 93.8% vs. 98.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.312) were similar between ABVD and A-AVD. Overall progression-free survival (PFS) and overall survival (OS) showed no significant differences between the two regimens (PFS p=0.489; OS\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.230). The 2-year PFS rates were 71.1% for ABVD and 76.7% for A-AVD. However, subgroup analysis revealed that in patients with Ann Arbor stage III-IV, a sufficient dose of BV (\u22651.15 mg\/kg) significantly improved PFS compared to a reduced dose (&amp;lt;1.15 mg\/kg) (2-year PFS 91.7% vs. 58.7%; p=0.036). Regarding safety, the A-AVD group exhibited a higher rate of peripheral neuropathy (47.1% vs. 5.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001), while pulmonary toxicity events were numerically more frequent in the ABVD group. The incidences of grade 3\u20134 neutropenia were comparable between the two groups (17.7% in ABVD vs. 19.6% in A-AVD,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.751).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first real-world study of frontline A-AVD-like therapy for cHL in China. Despite a higher proportion of elderly patients in A-AVD, the regimen still achieved a 2-year PFS rate of 76.7% and showed overall efficacy and survival outcomes comparable to the ABVD-like regimen. Notably, maintaining sufficient BV dose intensity (\u22651.15 mg\/kg) was significantly associated with superior PFS in patients with advanced-stage (Ann Arbor III-IV) disease. While A-AVD was associated with higher rates of peripheral neuropathy, ABVD showed a trend toward a higher risk of pulmonary toxicity. These findings support careful maintenance of BV dose intensity when clinically feasible, together with proactive toxicity management. Longer follow-up and larger prospective studies are needed to validate survival outcomes and toxicity profiles in Chinese patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1889698","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T04:20:29Z","timestamp":1783311629000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sufficient-dose Brentuximab vedotin improves prognosis in patients with classic Hodgkin lymphoma: a single-center real-world study in China"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhangyuting","family":"He","sequence":"first","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danqing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ruan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-2023","article-title":"Tislelizumab for relapsed\/refractory classical Hodgkin lymphoma: 3-year follow-up and correlative biomarker analysis","volume":"28","author":"Song","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001272","article-title":"Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-019-0788-0","article-title":"Controversies in the approach to initial therapy of Hodgkin lymphoma","volume":"21","author":"Allen","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00277-022-05054-9","article-title":"Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives","volume":"102","author":"Prince","year":"2023","journal-title":"Ann Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1201\/9781003433064-29","article-title":"Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma","volume":"93","author":"Eichenauer","year":"2014","journal-title":"Eur J Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718786833","article-title":"Update on the role of brentuximab vedotin in classical Hodgkin lymphoma","volume":"9","author":"Tomassetti","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0705-5","article-title":"Brentuximab vedotin: a review in CD30-positive Hodgkin lymphoma","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1636923","article-title":"Frontline brentuximab vedotin-based therapy for newly diagnosed classical Hodgkin lymphoma: a meta-analysis of randomized controlled trials","volume":"15","author":"Yang","year":"2025","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.756583","article-title":"Tumor flare reaction in a classic Hodgkin lymphoma patient treated with brentuximab vedotin and tislelizumab: a case report","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.03.015","article-title":"Real-world patient characteristics, treatment patterns, and outcomes for patients with stage III or IV classic Hodgkin lymphoma treated with frontline ABVD: a retrospective database review in the United States","volume":"23","author":"Winter","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(20)30275-1","article-title":"Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial","volume":"7","author":"Cheson","year":"2020","journal-title":"Lancet Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-2435","article-title":"Brentuximab vedotin plus chemotherapy in North American subjects with newly diagnosed stage III or IV Hodgkin lymphoma","volume":"25","author":"Ramchandren","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2838","article-title":"Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 study","volume":"39","author":"Hutchings","year":"2021","journal-title":"Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management","volume":"99","author":"Ansell","year":"2024","journal-title":"Am J Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104499","article-title":"Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma","volume":"204","author":"Abramson","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12462","article-title":"Paraneoplastic intrahepatic cholestasis in supradiaphragmatic classical Hodgkin lymphoma successfully treated with brentuximab vedotin: a case report and review of the literature","volume":"35","author":"Papakonstantinou","year":"2021","journal-title":"In Vivo"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged \u226560 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study","volume":"107","author":"Evens","year":"2022","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004645","article-title":"Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma","volume":"5","author":"Orellana-Noia","year":"2021","journal-title":"Blood Adv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024681","article-title":"Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma","volume":"145","author":"Lee","year":"2025","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019536","article-title":"Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy","volume":"143","author":"Friedberg","year":"2024","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/op.24.00089","article-title":"Protocol-stipulated dose modification to manage chemotherapy-induced peripheral neuropathy in children, adolescents, and young adults with high-risk Hodgkin lymphoma","volume":"21","author":"Heneghan","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"B24","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.clml.2024.05.017","article-title":"Phase I trial of brentuximab vedotin plus cyclosporine in relapsed\/refractory Hodgkin lymphoma","volume":"24","author":"Thiruvengadam","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1889698\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T04:20:30Z","timestamp":1783311630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1889698\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":24,"alternative-id":["10.3389\/fonc.2026.1889698"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1889698","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"article-number":"1889698"}}